[27], [29], [30]. Several of these antagonists are currently in phase I and II clinical trials [26], [31]. GLPG0187 is currently in phase Ib clinical trial for patients with a variety of solid tumors. The effect of blocking integrin receptors by GLPG0187 were similar to effects of knockdown of ITGAV in prostate cancer cells. These data indicate that ITGAV is functionally involved in the migratory, mesenchymal cellular phenotype of prostate cancer cells. Moreover, ITGAV is important for the acquisition of prostate cancer cells with a metastasis-initiating capacity [32]. This evidence concerns the gene ITGAV and prostate carcinoma.